AMF Tjanstepension AB Has $42.76 Million Stock Position in Stryker Corporation $SYK

AMF Tjanstepension AB reduced its holdings in Stryker Corporation (NYSE:SYK) by 30.4% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 130,128 shares of the medical technology company’s stock after selling 56,931 shares during the quarter. AMF Tjanstepension AB’s holdings in Stryker were worth $42,759,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the business. Sankala Group LLC bought a new stake in Stryker during the 4th quarter valued at approximately $26,000. Godfrey Financial Associates Inc. acquired a new position in Stryker during the 4th quarter valued at $26,000. United Financial Planning Group LLC bought a new stake in Stryker in the 3rd quarter valued at $27,000. Atlas Capital Advisors Inc. acquired a new stake in Stryker in the 4th quarter worth $27,000. Finally, DJE Kapital AG acquired a new stake in Stryker during the fourth quarter worth about $28,000. 77.09% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. BMO Capital Markets began coverage on Stryker in a report on Wednesday. They issued an “outperform” rating and a $369.00 price target for the company. UBS Group lowered their price objective on Stryker from $400.00 to $380.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 17th. The Goldman Sachs Group reissued a “neutral” rating and issued a $361.00 price target on shares of Stryker in a report on Friday, May 1st. Truist Financial restated a “hold” rating and issued a $330.00 price objective (down from $380.00) on shares of Stryker in a research note on Monday, May 4th. Finally, Argus set a $370.00 target price on shares of Stryker in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, Stryker has a consensus rating of “Moderate Buy” and an average price target of $392.87.

Insiders Place Their Bets

In related news, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares of the company’s stock, valued at $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP M Kathryn Fink sold 5,220 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the sale, the vice president directly owned 13,137 shares in the company, valued at $3,728,937.45. This trade represents a 28.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 323,264 shares of company stock valued at $100,659,489. 4.60% of the stock is currently owned by corporate insiders.

Stryker Trading Up 0.0%

Shares of Stryker stock opened at $329.86 on Monday. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $404.87. The stock has a market capitalization of $126.46 billion, a P/E ratio of 38.18, a price-to-earnings-growth ratio of 2.11 and a beta of 0.77. The company has a 50-day simple moving average of $310.12 and a 200 day simple moving average of $337.84. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The firm had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. Stryker’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter last year, the firm earned $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Research analysts expect that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be given a $0.88 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s payout ratio is presently 40.74%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.